Combination immunotherapy for B-cell acute lymphoblastic leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a combination of immune cells (CTL and DC vaccines) to target B-ALL. It may help patients with high levels of leukemia cells who have not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be older than 6 months.
- You must have a tumor sample with at least 30% blast cells (high burden) for vaccine preparation.
- Your cancer cells must show certain markers (CD19, CD22, CD20, CD10, or CD123).
- You must be relatively active and well (KPS score above 60) and expected to live more than 3 months.
- Your heart, lungs, liver, and kidneys must function adequately (e.g., heart pumping well, oxygen levels normal, creatinine and liver enzymes within limits).
- You must not have any condition that prevents cell separation (like certain blood disorders).
- You must understand and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two different engineered immune cell therapies to treat B-ALL (a leukemia). It’s designed for young people whose disease has come back, is hard to treat, or didn’t respond well to similar cell therapies.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target leukemia cells after chemotherapy has put your disease into remission. The goal is to help prevent the leukemia from coming back, especially for patients at high risk of relapse.
This trial tests a new cell therapy (QH103) for people with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. The therapy uses specially modified immune cells to find and kill cancer cells that have a protein called CD19 on their surface.
This trial tests a 'universal' CAR-T cell therapy for B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to at least two prior treatments. The goal is to see if these special immune cells can safely find and destroy the cancer.
This trial tests a treatment plan that uses blinatumomab (a drug that helps your immune system attack leukemia cells) combined with your own stem cell transplant. It is for people with B-ALL who cannot or choose not to have a transplant from another person.
This trial tests whether adding targeted drugs to standard chemotherapy works better for adults newly diagnosed with T-ALL. If you have not had any prior treatment for leukemia, this study might be an option.
Hear when a new B-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.